Connect with us


Alfasigma Buys the Drug Jyseleca from Galapagos for €170 Million

Alfasigma’s Spanish subsidiary is expanding its facilities in Tortosa, Barcelona, to increase production capacity. The subsidiary, created in 2015 through the merger of Sigma-Tau and Alfa Wasserman, focuses on the production of Filgotinib, a treatment for rheumatoid arthritis and ulcerative colitis. The facility employs 1,475 people and occupies 1,600 square meters.




Alfasigma expands its portfolio. The Italian group has purchased the drug Jyseleca from Galapagos for €170 million, in an operation that will close during the first quarter of 2024. The scientist’s treatment is aimed at patients with ulcerative colitis and rheumatoid arthritis (RA), according to the company statement.

Following the acquisition of the drug, Alfasigma intends to carry out a phase three clinical trial to develop a third indication for the therapy. Galapagos itself will also participate in this phase, investing forty million euros until June 2025 .

The Italian pharma will buy the entire business of Jyseleca, including marketing authorizations in Europe and the United Kingdom, commercial and medical affairs and drug development activities. Additionally, it will acquire approximately 400 Galapagos positions in fourteen European countries. In this sense, the seller will receive an initial payment of fifty million euros, possible milestone payments totaling €120 million and payments based on European sales.

Read more about Alfasigma and the buying of Jyseleca from Galapagos and fidn the most important financial news of the day with the Born2Invest mobile app.

Jyseleca is aimed at patients with ulcerative colitis and rheumatoid arthritis

Filgotinib is marketed as Jyseleca in Europe and Japan for the treatment of adults with moderately to severely active RA who have responded inadequately or are intolerant to one or more disease-modifying antirheumatic drugs . Filgotinib is also used for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic agent.

The Spanish subsidiary of Alfasigma is located in Tortosa, Barcelona, ​​and occupies an area of ​​1,600 square meters . 1,475 people work there and it has a portfolio of fifty references. The Spanish delegation of the company is the result of the merger in 2015 of Sigma-Tau and Alfa Wasserman and, previously, of the union of Geve Laboratories, in Tortosa, with Bama Laboratories, in 2003.

For its part, Galapagos is a global biotechnology company with operations in Europe and the United States dedicated to the development of transformative medicines to achieve longer and higher quality of life. The company combines science, technology and collaborative approaches to create a portfolio of therapies and biologics in oncology and immunology.


(Featured image by frolicsomepl via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.